Cytek IPO Presentation Deck

Cytek's Value Proposition to the Clinical Market M 22 NL-CLC M ■ Benefits ▪ Allows for more informative antibodies in one tube Minimizes use of redundant reagents Optimizes use of smaller amounts of patient specimen Identifies small populations of abnormal cells Improves overall laboratory efficiency Lowers costs . . Performs high-level multi-parameter flow cytometry immunophenotyping on small sample amounts ■ Accurately detects, diagnoses and monitors immune cell disorders with very low levels of key biomarkers Becoming a Solutions Provider for the Clinical Market Weite Automated Sample Preparation Customized Workflow Solutions Automated Analysis Error Reduction CYTEK 26

View entire presentation